Disease Landscape and Forecast Insights

In 2021, sales of branded biologics in oncology, immunology, endocrinology, nephrology, respiratory, and ophthalmology exceeded $130 billion in the major pharmaceutical markets under study (United…

Payers play a significant role in determining the commercial success of biosimilars—as well as their reference brands—as they decide which products are granted formulary access and preferential…

The biosimilar / follow-on insulin sector of the diabetes therapy market is evolving. Eli Lilly / Boehringer Ingelheim’s Abasaglar / Basaglar was the first biosimilar / follow-on insulin glargine…

In 2019, sales of branded biologics in ophthalmology reached almost $9 billion in the major pharmaceutical markets (United States, EU5, and Japan). Throughout our 2019-2029 forecast period,…

In 2019, sales of insulins at the ex-manufacturer price level exceeded $11 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2019-2029 forecast…

In 2019, sales of erythropoiesis-stimulating agent (ESA) brands and biosimilars at the ex-manufacturer price level totaled almost $3.98 billion in the major pharmaceutical markets under study (…

In 2019, sales of branded biologics in immunology exceeded $70 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Major-market sales of biosimilars in this…

Celltrion’s Herzuma was the first biosimilar of Roche’s Herceptin, a blockbuster HER2-targeted therapy, to launch in Europe. A few months later, two additional trastuzumab biosimilars launched…

The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 600 currently available and novel biosimilar products, detailing…

The development and commercialization of biosimilars require significant investment in capital, resources, and time. Biosimilars developers must ensure that they are equipped with the necessary…

The regulatory and market access landscape for biosimilars is constantly evolving. For a company seeking to develop a biosimilar for multiple markets, keeping track of the similarities and…

Since the approval of the first biosimilar in Europe more than a decade ago, the adoption of biosimilars has been increasing among all specialties. The FDA approved Sandoz’s Zarxio (filgrastim)…